NCT05233098View on ClinicalTrials.gov

TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.

CompletedOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

Technetium-99m macroaggregated albumin (Tc-99m MAA)

Patients who are being evaluated for TheraSphere administration.

Trial Locations (1)

60611

Northwestern University, Chicago

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT05233098 - TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | Biotech Hunter | Biotech Hunter